|
|
On Demand Webinar: Emerging Impact of Zebrafish Technology on Preclinical Safety
Cambridge Healthtech Associates' complimentary web conference entitled, The Emerging Impact of Zebrafish Technology on Preclinical Safety Decision Making, was originally held on Wednesday, July 9, 2008 at 11:00 AM EDT (5:00 PM CEST).
Register for the On-Demand recording and slides using the form below.
This complimentary, online session featured the following expert panel:
- Ernie Bush, Ph.D., Vice President and Scientific Director, Cambridge Healthtech Associates
- David Brewster, Ph.D., Vice President, Nonclinical Safety, F. Hoffman-La Roche
- Derek Leishman, Ph.D., Research Fellow, Global Safety Pharmacology, Lilly Research Laboratories
- George C. McCormick, Ph.D., D.A.B.T., Vice President, Drug Safety & Disposition, Cephalon, Inc.
- Nina Sawczuk, Chief Executive Officer, Zygogen, LLC
The panel discussed a number of issues during the session:
- Why do you think biopharm companies are beginning to seriously consider and/or evaluate the integration of zebrafish technology into their assortment of preclinical screens?
- What are the advantages of testing in vivo with zebrafish vs. other in vivo & in vitro screens and profiling tools?
How important is the determination of drug exposure to the eventual widespread adoption of zebrafish safety testing technology?
Zebrafish are currently being evaluated as models to ‘predict’ many different adverse effects; which do you think will be the most valuable and why?
What concerns you the most about the possibility of zebrafish being incorporated into preclinical safety assessment paradigms?
|